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Previously, the pleiotropic “master kinase” casein kinase 2 (CK2) was shown to interact with CFTR, the
protein responsible for cystic fibrosis (CF). Moreover, CK2 inhibition abolished CFTR conductance in cell-
attached membrane patches, native epithelial ducts, and Xenopus oocytes. CFTR possesses two CK2 phosphor-
ylation sites (S422 and T1471), with unclear impact on its processing and trafficking. Here, we investigated the
effects of mutating these CK2 sites on CFTR abundance, maturation, and degradation coupled to effects on ion
channel activity and surface expression. We report that CK2 inhibition significantly decreased processing of
wild-type (wt) CFTR, with no effect on F508del CFTR. Eliminating phosphorylation at S422 and T1471 revealed
antagonistic roles in CFTR trafficking: S422 activation versus T1471 inhibition, as evidenced by a severe
trafficking defect for the T1471D mutant. Notably, mutation of Y512, a consensus sequence for the spleen
tyrosine kinase (SYK) possibly acting in a CK2 context adjacent to the common CF-causing defect F508del, had
a strong effect on both maturation and CFTR currents, allowing the identification of this kinase as a novel
regulator of CFTR. These results reinforce the importance of CK2 and the S422 and T1471 residues for
regulation of CFTR and uncover a novel regulation of CFTR by SYK, a recognized controller of inflammation.
Cystic fibrosis (CF) is the most common lethal genetic dis-
ease among Caucasians and is characterized by a chronic, de-
structive inflammatory lung disease as the major cause of mor-
tality (5). CF is caused by mutations in the gene encoding the
CF transmembrane conductance regulator (CFTR) protein, a
polytopic integral membrane protein that functions as a cyclic
AMP (cAMP)-activated chloride (Cl) channel and regulator
of other channels at the apical membrane of epithelial cells
(31). CFTR is a member of the ATP-binding cassette (ABC)
transporter superfamily, and its structure includes two trans-
membrane domains (TMD1 and -2) that form the pore of the
channel, two nucleotide binding domains (NBD1 and -2), and
a regulatory domain (RD) containing several phosphorylation
sites. Activation of CFTR occurs through binding of ATP and
dimerization of the two NBDs, along with phosphorylation of
the R domain by protein kinase A (PKA) at multiple phos-
phorylation sites (4, 22, 42).
CFTR is inserted cotranslationally into the endoplasmic re-
ticulum (ER) membrane (17), where the ER quality control
machinery targets a fraction of wild-type (wt) CFTR and al-
most all the protein bearing F508del (the most common mu-
tation, present in about 70% of CF chromosomes) for degra-
dation at the proteasome (15). F508del CFTR is partially
functional when it is induced to traffic to the cell membrane
(29, 35). The regulation of normal and mutant CFTR intracel-
lular trafficking and activity is the result of a complex network
of proteins which includes molecular chaperones (9, 10, 18),
glycan-processing enzymes, and other transporters and chan-
nels (3) as well as the basal trafficking machinery (Rab
GTPases, SNAREs, or PDZ domain proteins) (11, 28) and
molecular switches (kinases and phosphatases). Together with
PDZ domain-containing proteins, phosphorylation is involved
in the formation of multiprotein signaling complexes that pro-
vide spatial and temporal specificity to CFTR function (14).
However, its role in CFTR trafficking has so far remained
unknown.
A previous study demonstrated that CK2 colocalized with wt
CFTR in apical membranes of airway epithelial cells (39). It
was found that inhibition of CK2 attenuates CFTR-dependent
Cl transport in overexpressing cells, Xenopus laevis oocytes,
and pancreatic ducts expressing wild-type CFTR. CK2 inhibi-
tion promptly closed CFTR Cl channels in cell-attached
membrane patches and reduced the conductance of CFTR-
expressing oocytes by about 80%. Moreover, coimmunopre-
cipitation suggested a direct interaction of wt CFTR but not of
F508del CFTR with CK2. Interestingly, F508del CFTR Cl
currents were insensitive to CK2 inhibitors, and a peptide
mimicking the F508del region of CFTR failed to inhibit CFTR
activity, whereas the wild-type peptide blocked CFTR function
(39).
This early work hinted at a complexity of underlying protein-
protein interactions involving CK2 and CFTR because no sig-
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nificant inhibitory effect of pharmacological CK2 inhibition on
CFTR function could be observed in excised patches of mem-
branes detached from the very same cells that had just dem-
onstrated prompt CFTR closure after 80 s of CK2 inhibition in
the cell-attached mode (39). Subsequently, in vitro data sug-
gested that a serine at position 422 within NBD1 was phos-
phorylated by CK2 with the surprising finding that the most
likely candidate site at S511 near F508 was not labeled (26).
Apart from this, there is only one preliminary report of an-
other potential CK2 motif in the C-terminal end of CFTR
(T1471) located within an acidic cluster (25).
Recent results point to a role for F508, S511, and nearby
amino acids such as V510 in the allosteric control of the major
structural forms of CK2 found in cells (27). These data are
consistent with a model where the CFTR F508del peptide
could bind different sites on isolated CK2alpha subunits than
on the CK2(alpha/beta)2 homodimer and suggest that CK2
targeting to subsets of its many targets may be perturbed in
cells expressing F508del CFTR (27).
Interestingly, CFTR has a consensus for protein phosphor-
ylation for spleen tyrosine kinase (SYK) at a nearby residue,
i.e., Y512, consisting of a tyrosine followed by two negative
residues (Y-E/D-E/D-X) (24). SYK is a cytosolic nonreceptor
tyrosine kinase present in many cells, mainly involved in the
regulation of the inflammatory process (30).
Since CK2 has been suggested to function as a multikinase
anchor to CFTR, involving single protein kinases such as nu-
cleoside diphosphate kinase (NDPK) and AMP-activated ki-
nase (AMPK) (20), the proximity of Y512 with F508 and S511
may also account for an interplay of CK2 and SYK on CFTR
traffic and function.
Because the roles of the different CK2 phosphorylation sites
are poorly understood, we examined in detail their impact on
maturation and Cl channel function of CFTR. Our data sug-
gest an antagonistic role of residues S422 and T1471 in the
regulation of CFTR function and trafficking by CK2. Our data
confirm regulation of CFTR by SYK, which interacts with
CFTR in the in vivo phosphorylating of NBD1 at Tyr512, but
exclude any role for residue S511 in the functional interaction
of CFTR and CK2 by using a number of CFTR mutants.
MATERIALS AND METHODS
Site-directed mutagenesis, cells, and CFTR expression. By using the
QuikChange mutagenesis kit (Stratagene, La Jolla, CA), we introduced muta-
tions into CFTR in the pNUT or the pBluescript vector (32, 37). BHK cells were
transfected with 2 g of each pNUT-CFTR variant by using Lipofectamine 2000
(Invitrogen, Carlsbad, CA) and selected for stable transfectants by using 500 M
methotrexate. After 10 days, individual clones were isolated and assessed for
CFTR expression by Western blotting (WB).
Western blotting. WB was performed as described previously (10). Briefly,
cells were lysed with sample buffer (1.5% [wt/vol] SDS, 5% [vol/vol] glycerol,
0.001% [wt/vol] bromophenol blue, 0.5 mM dithiothreitol [DTT], and 31.25 mM
Tris, pH 6.8). Total protein was quantified by a modified micro-Lowry method,
and 30 g of total protein was loaded onto 7% (wt/vol) SDS-PAGE gels for
electrophoretic separation and transferred onto polyvinylidene difluoride
(PVDF) filters. The filters were probed with the anti-CFTR monoclonal antibody
(MAb) 596 (CFF, Bethesda, MD) to detect specifically CFTR and the Super-
Signal West Pico chemiluminescent substrate system (Pierce, Rockford, IL) to
develop WB. As a loading control, blots were reprobed with the anti--actin Ab
(Sigma). Films were digitalized on an ImageScanner (GE Healthcare). Inte-
grated peak areas were determined using the gel analysis ImageQuant software
(GE Healthcare).
Pulse-chase and immunoprecipitation. Cells expressing CFTR were starved
for 30 min in methionine-free medium and then pulsed for 30 min at 37°C in the
same medium supplemented with 150 Ci [35S]methionine. Pulse-chase experi-
ments, followed by immunoprecipitation (IP) with an anti-CFTR MAb, were
performed as previously described (10). Briefly, after chasing for 0, 0.5, 1, 2, and
3 h in regular medium with 5% (vol/vol) fetal bovine serum and 1 mM nonra-
dioactive methionine, cells were lysed in 1 ml of RIPA buffer (1% [wt/vol]
deoxycholic acid, 1% [vol/vol] Triton X-100, 0.1% [wt/vol] SDS, 50 mM Tris, pH
7.4, and 150 mM NaCl) and immunoprecipitation of CFTR was carried out with
1 g of MAb 596 (CFF, Bethesda, MD) or MAb M3A7 (Chemicon) and protein
G-agarose beads. Immunoprecipitated proteins were eluted for 1 h at room
temperature in sample buffer (see above) and then electrophoretically separated
by SDS-PAGE. SDS-PAGE, fluorography, densitometry, and statistical analysis
were also performed as described previously (10). The number of cells used for
labeling and immunoprecipitation experiments was 2  106 cells for each time
point. Densitometry was performed as described above.
Coimmunoprecipitation. Cells were grown in 100-mm plates and lysed on ice
in 1 ml nondenaturing lysis buffer (50 mM Tris-HCl, pH 7.5, 1% NP-40, 100 mM
NaCl, 10% glycerol, 10 mM MgCl2) supplemented with a protease inhibitor
cocktail. The cell lysates were precleared with protein G-agarose beads for 1 h at
4°C, then incubated for 2 h at 4°C with either anti-SYK polyclonal Ab (PAb)
(sc-929; Santa Cruz Biotechnology, Santa Cruz, CA) or anti-CFTR 596 MAb,
then further incubated for 1 h with protein G-agarose beads (Roche Applied
Science, Indianapolis, IN), and finally washed three times in cold lysis buffer
containing 200 mM NaCl. Proteins were solubilized from the beads in 2 SDS
sample buffer and separated by 10% SDS-polyacrylamide gel electrophoresis.
WB was performed as described above with anti-SYK PAb.
In vitro phosphorylation. For in vitro protein kinase assays, 1 g of a recom-
binant fragment of human CFTR (amino acids corresponding to the first nucle-
otide binding domain, NBD1 [36]) was resuspended in 20 l kinase reaction
buffer (30 mM Tris-HCl, pH 7.5, 10% [vol/vol] glycerol, 1 mM DTT, 1 mM
Na3VO4, 37.5 mM MgCl2, and 250 M ATP) and incubated in the presence of
5 mCi [-32P]ATP at 30°C for 30 min with beads containing either immunopre-
FIG. 1. Regulation of Cl transport in native epithelial cells by
CK2. (A) Original Ussing chamber recording from a mouse colon
measured under open-circuit conditions, showing the lumen-negative
transepithelial voltage generated by the transport activity of the tissue.
Stimulation of tissue by IBMX/forskolin (100 M/2 M, respectively)
induced a negative voltage deflection due to activation of Cl secre-
tion. Reversible inhibition of the Cl secretion by TBB (10 M).
(B) Dose-response curve for the inhibitory effects of TBB on IBMX
(100 M)- and forskolin (5 M)-induced Cl secretion in excised
mouse trachea as measured in Ussing chamber recordings. (C) Sum-
mary of the calculated equivalent short-circuit currents demonstrating
inhibition of IBMX/forskolin-activated transport by TBB (10 M) in
both mouse colon and trachea. Data indicate means  standard errors
of the means. Numbers in parentheses are the numbers of experi-
ments. Asterisks indicate significant inhibition by TBB (paired t test).
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cipitated green fluorescent protein (GFP) or yellow fluorescent protein (YFP)-
SYK protein. Then, 5 Laemmli SDS sample buffer was added to the reaction
mixtures and proteins were separated by SDS-PAGE followed by transfer to a
PVDF membrane. The membrane was first analyzed by autoradiography fol-
lowed by WB using the indicated antibodies.
Cell surface biotinylation. BHK cells stably expressing CFTR variants were
washed twice with warm culture medium to remove dead cells and placed on ice
in a cold room. Cells were washed three times with ice-cold PBS-CM (phosphate-
buffered saline [PBS], pH 8.0, containing 0.1 mM CaCl2 and 1 mM MgCl2) and
left for 5 min in cold PBS-CM to ensure arrest of endocytic traffic. Cells were
then incubated for 30 min with 0.5 mg/ml EZ-Link sulfo-NHS-SS-biotin (Pierce
Biotechnology, Rockford, IL; catalog no. 21331) in PBS-CM before being rinsed
twice and left for 15 min on ice with ice-cold Tris-glycine (100 mM Tris-HCl, pH
8.0, 150 mM NaCl, 0.1 mM CaCl2, 1 mM MgCl2, 10 mM glycine, 1% bovine
serum albumin [BSA]) to quench the biotinylation reaction. Cells were again
washed three times with cold PBS-CM and lysed in 250 l pulldown buffer (50
mM Tris-HCl, pH 7.5, 100 mM NaCl, 10% glycerol, 1% NP-40) in the presence
of a protease inhibitor cocktail composed of 1 mM phenylmethylsulfonyl fluoride
(PMSF), 1 mM 1,10-phenanthroline, 1 mM EGTA, 10 M E64, and 10 g/ml
each of aprotinin, leupeptin, and pepstatin A (all from Sigma-Aldrich Quimica,
Madrid, Spain). The cell lysates were harvested by scraping and cleared by
centrifugation at 16,000  g at 4°C for 5 min. An aliquot of 40 l representing
the total CFTR level was removed and added to 2 CFTR sample buffer (62.5
mM Tris-HCl, pH 6.8, 3% SDS, 10% glycerol, 0.02% bromophenol blue, 160
mM DTT), while 200 l lysate was added to 25 l streptavidin-agarose beads
(Sigma-Aldrich) previously incubated for 1 h in 1 ml cold pulldown buffer
containing 2% nonfat milk powder and washed three times in pulldown buffer.
For purification of biotinylated proteins, lysate and beads were incubated under
rotation for 1 h at 4°C and the beads were collected by centrifugation (1 min at
3,000 g) and washed three times in cold wash buffer (100 mM Tris-HCl, pH 7.5,
300 mM NaCl, 1% Triton X-100). Captured proteins were recovered from the
beads in 25 l 2 CFTR sample buffer. The biotinylated protein fraction and
whole-cell lysates were analyzed in parallel by SDS-PAGE followed by WB.
cRNA and DEVC. cRNA syntheses were performed based on in vitro tran-
scription techniques, using T7, T3, or SP6 promoter and polymerase (Promega).
Xenopus laevis oocytes were defolliculated by incubation at 18°C for 1 h with
collagenase V (Sigma) in OR2 solution (82.5 mM NaCl, 2 mM KCl, 1 mM
MgCl2, and 5 mM HEPES, pH 7.55). Oocytes were injected with 10 ng cRNA (in
a total volume of 47 nl) encoding wt, S422A, S422D, Y512A, Y512D, Y512F,
T1471A, T1471D, F508del, F508del-S422A, F508del-S422D, F508del-Y512A,
F508del-Y512D, F508del-Y512F, F508del-T1471A, or F508del-T1471D CFTR.
Oocytes were incubated at 18°C for 2 to 4 days in ND97 solution (96 mM NaCl,
2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, 2.5 mM sodium
pyruvate, 0.5 mM theophylline, and 0.01 mg/ml gentamicin, pH 7.55) before
subjection to double-electrode voltage clamp (DEVC). Whole-cell currents were
measured by impaling the oocyte membrane with two electrodes (Clark Instru-
FIG. 2. Turnover and processing of wt and F508del CFTR under treatment with the CK2 inhibitor TBB. BHK cells stably expressing wt (A) or
F508del (B) CFTR were treated for 90 min with 20 M TBB or with the same volume percentage of dimethyl sulfoxide (DMSO) as a control. After
preincubation with TBB, cells were pulse-labeled for 30 min with [35S]methionine and chased for 0, 0.5, 1, 2, and 3 h. Cells were then lysed and
immunoprecipitated with an anti-CFTR M3A7 Ab. Following electrophoretic separation and fluorography, immature (band B) and mature (band
C) forms of CFTR were quantified with the ImageQuant software. Turnover of the core-glycosylated form (band B) of wt (C) and F508del
(D) CFTR is shown as the ratio between P, the amount of band B at time t, and P0, the amount of band B at the start of the chase (i.e., at the
end of pulse). The efficiency of conversion of the core-glycosylated form (band B) into the fully glycosylated form of wt CFTR (band C) was also
estimated for wt CFTR (E) and determined as band C at time t as a percentage of the amount of band B at the start of the chase (P0). Images
are representative of a total of three experiments.
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ments Ltd., Salisbury, United Kingdom) that were filled with 3 M KCl and had
a resistance less than 1 M. Membrane voltages were clamped (oocyte clamp
amplifier; Warner Instruments LLC, Hamden, CT) from 60 to 40 mV. The
bath was continuously perfused at a rate of 5 ml/min. The voltage drop across the
serial resistance was adjusted to zero by two bath electrodes and a virtual-ground
head stage. All experiments were conducted in ND96 solution (96 mM NaCl, 2
mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, and 2.5 mM sodium
pyruvate, pH 7.55) at room temperature (22°C).
Animals and Ussing chamber experiments. Animal studies were conducted
according to the German laws on protection of animals. Mice (C57BL/6; Charles
River, Germany) were sacrificed under CO2 narcosis by cervical dislocation.
Mouse tracheas were dissected, opened longitudinally on the opposite side of the
cartilage-free zone, and transferred immediately into an ice-cold buffer solution.
Stripped colon was put into an ice-cold bath solution (145 mM NaCl, 0.4 mM
KH2PO4, 1.6 mM K2HPO4, 6 mM D-glucose, 1 mM MgCl2, 1.3 mM calcium
gluconate, pH 7.4) containing amiloride (10 M) and indomethacin (10 M).
Experiments were performed as described previously (1). Briefly, after being
mounted into a perfused micro-Ussing chamber, apical and basolateral surfaces
of the epithelium were perfused continuously with buffer solution at a rate of 5
to 10 ml/min (chamber volume, 2 ml). All experiments were carried out at 37°C
under open-circuit conditions. Transepithelial resistance (Rte) was determined
by applying short (1-s) current pulses (I  0.5 A) and the corresponding
changes in transepithelial voltage (Vte) and basal Vte were recorded continuously.
Values for Vte were referred to the serosal side of the epithelium. The equivalent
short-circuit current (Isc) was calculated according to Ohm’s law from Vte and Rte
(Isc  Vte/Rte).
Materials and statistical analysis. All compounds used were of the highest
available grade of purity and were from Sigma (St. Louis, MO) or Calbiochem
(San Diego, CA). The compounds used in this study were usually applied at
recommended maximal concentrations to achieve full activation or inhibition.
For statistical analysis, the Student t test was used to compare any two different
groups. Differences in multiple groups were analyzed using one-way analysis of
variance (ANOVA) followed by the Tukey test to compare significant differences
between individual groups. P values of 0.05 were considered significant.
RESULTS
Regulation of CFTR by CK2 is important in mouse colonic
and airway epithelia. Previous observations show that CK2-
dependent regulation is observed not only in CFTR-overex-
pressing cells but also in excised epithelial tissues (25, 39). To
test our hypothesis that CK2 is an important regulator of
CFTR under physiological conditions, we extended these stud-
ies to native mouse epithelial tissues. We removed mouse
distal colon and trachea from sacrificed animals and performed
open-circuit Ussing chamber recordings. The lumen-negative
transepithelial voltage was enhanced by stimulation of mouse
colon with isobutylmethylxanthine (IBMX; 100 M) and for-
skolin (Fors; 2 M). Almost all the entire short-circuit current
(Isc) that was activated by IBMX and forskolin is CFTR, since
5 M CFTRinh172 reduced IBMX/Fors (I/F)-activated Isc
from 248  29 A/cm2 to 61  19 A/cm2 (n  4, colon) and
from 158  12 A/cm2 to 41  13 A/cm2 (n  5, trachea).
Application of the CK2 inhibitor TBB (4,5,6,7-tetrabromo-
benzotriazole; 10 M) in the presence of IBMX/forskolin in-
hibited the transepithelial voltage reversibly, thus demonstrat-
ing inhibition of CFTR that had been previously activated by
IBMX/forskolin (Fig. 1A). When calculating the equivalent
short-circuit current (Isc), we found significant inhibition of
IBMX/forskolin-induced Isc by TBB in both distal colonic and
airway epithelium (Fig. 1C). Importantly, our earlier work
demonstrated that TBB was highly selective for CK2 by show-
ing that coexpression of a TBB-insensitive form of CK2 elim-
inated the ability of TBB to inhibit PKA-activated CFTR (39).
In addition, we observed that the onset of the inhibition with
TBB occurred at about 1 M, a concentration that is highly
specific for CK2 (Fig. 1B). Thus, these combined data indicate
that CK2 is an important regulator of CFTR-dependent Cl
transport in native epithelia and that TBB is a specific phar-
macological agent for the further investigation of the role of
CK2 in CFTR function. Inhibition of IBMX/Fors-activated Isc
by TBB was also confirmed using another CK2 inhibitor,
quinalizarin (5 M) (6). Application of quinalizarin reduced
the Isc by 81%  11% (n  3; colon) and by 79%  16% (n 
3; trachea) (data not shown).
CFTR turnover and processing under CK2 inhibition. In
order to define the role of CK2 in CFTR turnover and pro-
cessing, we assessed the concomitant effects of the inhibition of
the kinase by a pulse-chase approach. For this, cells were
incubated for 90 min with the CK2 inhibitor TBB before per-
forming pulse-chase and immunoprecipitation (IP) of CFTR
and the experiments were performed still in the presence of
the inhibitor. We also assessed cell viability to exclude any
effect of incubation with TBB (data not shown).
The results in Fig. 2 show that 20 M TBB both increases the
turnover of immature wt CFTR (Fig. 2B) and decreases the
efficiency of its processing into the mature glycosylated form
(band C, Fig. 2A and dashed lines in Fig. 2C and E). This effect
occurs despite the expected suppressive effects of CK2 inhibi-
tion of protein synthesis given that CK2 controls up to 75% of
cell proliferation (compare left and right panels in Fig. 2A and
B, normalized to starting abundance in Fig. 2C, D, and E). In
contrast, CK2 inhibition by TBB does not produce any detect-
able effect upon the turnover of immature F508del CFTR (Fig.
2D). These results show that CK2 activity affects the stability of
FIG. 3. Steady-state levels of CFTR bearing S422, S511, and T1471
mutations. (A) WB of total protein (30 g) from BHK cells stably
expressing CFTR bearing different mutations. Actin was also assessed
as a loading control. (B) Processing of CFTR at steady state was
assessed by densitometry and shown as the ratio of band C to total
CFTR (C/B	C), normalized to wt CFTR (black bars). The amount of
mature band C CFTR was also assessed as ratio of band C to actin,
again normalized to wt CFTR (grey bars). Asterisks indicate significant
differences from wt CFTR (t test, P 
 0.05).
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the immature form of wt CFTR (but not F508del CFTR) and
its trafficking through the Golgi complex, here detected by the
delayed and attenuated appearance of its fully glycosylated
form (Fig. 2E). Thus, these data suggest that TBB reduces
band B stability, accelerates its destruction, and delays band C
appearance by around 30 min (Fig. 2A, C, and E, respectively).
Mutation of consensus CFTR sites for CK2 phosphoryla-
tion. Since we found that CK2 inhibition affects wt CFTR
processing, our next aim was to investigate the molecular
mechanism of this effect. To this end, we screened CFTR
sequence both manually and using NetPhosK1.0 phosphoryla-
tion site prediction software (2) so as to identify potential
FIG. 4. Turnover and processing of CFTR bearing S422, S511, and T1471 mutations. BHK cells stably expressing S422A or S422D CFTR (A), S511A
or S511D CFTR (D), and T1471A or T1471D CFTR (G) were analyzed by pulse-chase as in Fig. 2 followed by immunoprecipitation with anti-CFTR
M3A7 or 596 antibodies. Electrophoresis, fluorography, and quantification were also performed as in Fig. 2. Turnover of the core-glycosylated form (band
B) of S422A/D (B), S511A/D (E), and T1471A/D CFTR (H) is shown as the ratio between P, the amount of band B at time t, and P0, the amount of
band B at the start of the chase (i.e., at the end of pulse). The efficiency of conversion of the core-glycosylated form (band B) into the fully glycosylated
form of wt CFTR (band C) was also estimated for S422A/D (C), S511A/D (F), and T1471A/D CFTR (I) and determined as the percentage of band C
at time t relative to the amount of band B at the start of the chase (P0). Images and quantitations are representative of a total of 3 to 4 experiments.
Asterisks in panel I indicate differences from wt CFTR for the time points indicated (t test, P 
 0.05).
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consensus sites for CK2 phosphorylation, a serine or threonine
residue specified by an acidic side chain at position n 	 3
(S/T-x-x-E/D/pS) (19), and found the presence of 21 putative
CK2 phosphorylation sites in CFTR: S4, T360, T388, S422,
T501, S511, T582, S605, T629, S678, T803, T816, T990, T1121,
T1149, T1211, T1263, S1311, S1326, S1442, and T1471.
Based on their predicted functionality, we chose three spe-
cific sites to proceed with further analyses, namely, (i) S422,
which was shown in vitro to be a CK2 phosphorylation site in
purified wt NBD1 (26); (ii) S511, for being exposed on the
surface of NBD1 very close to the site of the most common
CF-causing mutation (F508del) and previously identified as
important for CK2-dependent regulation of CFTR function as
a channel (39); and (iii) T1471 in the vicinity of the C-terminal
regulatory site for NHERF1 anchoring and membrane traffic
(25).
We used site-directed mutagenesis to replace these specific
sites in wt CFTR with either an alanine (A) or an aspartate
(D). The resultant cDNAs were used to create stably express-
ing BHK cell lines. CFTR variants were analyzed by WB to
assess the steady-state levels of the different variants (Fig. 3),
which showed that mutation of S422 or S511 to either A or D
does not affect the processing of CFTR at steady state, as-
sessed by mature CFTR (band C) as a percentage of total
CFTR, i.e., immature CFTR (band B) plus band C (Fig. 3B).
However, a pronounced effect is observed for both T1471
variants, with the presence of T1471A decreasing significantly
the processing of CFTR at steady state by around 25% and
with T1471D completely abolishing the appearance of the fully
glycosylated form (Fig. 3A and B, last lanes).
Turnover and processing of CFTR bearing S422, S511, and
T1471 mutations. The effect of these mutations on the turn-
over and processing of CFTR was then studied by the meta-
bolic pulse-chase approach (Fig. 4A, D, and G, respectively).
Analysis of results for either S422 or S511 mutants (Fig. 4B and
E, respectively) shows that neither the turnover rate of the
immature form (band B) nor its efficiency of processing into
the mature glycosylated form (band C) is altered (Fig. 4C and
F, respectively). However, pulse-chase experiments performed
for T1471A/D CFTR variants show that mutation of T1471
slightly increases the turnover of band B (Fig. 4H). Moreover,
the presence of T1471A significantly decreases processing ef-
ficiency of CFTR and T1471D completely impairs the appear-
ance of its fully glycosylated form (Fig. 4I has no data points
for T1471D), which explains the findings in Fig. 3. For T1471D,
FIG. 5. Identification of functionally relevant CK2 sites in CFTR. (A) Whole-cell current measured in a wt-CFTR-expressing oocyte before and
after activation by IBMX/forskolin (I/F; 1 mM/2 M, respectively) and effects of the CK2 inhibitor TBB (10 M). (B) Summary of the calculated
IBMX/forskolin-activated whole-cell conductances for wt CFTR and CFTR mutants and whole-cell conductances in the presence of TBB.
(C) Whole-cell conductances of CFTR mutants relative to wt CFTR. (D) TBB-inhibited whole-cell conductances of CFTR mutants relative to wt
CFTR. Data indicate means  standard errors of the means. Numbers in parentheses are numbers of experiments. Asterisks indicate significant
inhibition by TBB (B) and significant difference from wt CFTR (unpaired t test and ANOVA) (C and D).
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we found a trend for faster disappearance of band B but a
complete absence of band C.
Taken together, these results show that the CFTR S422
residue, although identified in vitro as a phosphorylation site
for CK2, does not affect the trafficking of the protein in
living cells. The same is observed for the S511 residue, which
also appears not to be a critical spot for regulation of CFTR
turnover and processing. In sharp contrast, the T1471 resi-
due, previously described as a site for CFTR phosphoryla-
tion by CK2 (25), seems to be critical for CFTR turnover
and processing.
Identification of functionally relevant CK2 sites in CFTR.
We then characterized the functional effects of these CK2 site
variants of CFTR upon channel conductance. First, we ex-
pressed wt CFTR in Xenopus oocytes and activated it by stim-
ulation with IBMX (1 mM) and forskolin (2 M) in the ab-
sence and in the presence of the CK2 inhibitor TBB (Fig. 5A).
Whole-cell currents that were measured in CFTR-express-
ing oocytes after stimulation with IBMX and forskolin were
due to activation of wt CFTR. The baseline conductance of
4.6  0.7 S (n  15) measured under control conditions was
increased by I/F to 83  7 S and was reduced by 5 M
CFTRinh172 to 14.7  3.7 S. Calculation of the IBMX/
forskolin-activated whole-cell conductance clearly indicated
significant inhibition by TBB (Fig. 5B, bars 1 and 2) (by 53%
7%). Next, we expressed the CK2-phosphorylation CFTR mu-
tants with mutations of S422 and T1471 to either alanines or
aspartates, as well as the SYK-phosphorylation CFTR mutant
Y512, to test whether the latter affects the phosphorylation of
CFTR by CK2 (19). In Xenopus oocytes, all of these mutants
produced significant whole-cell currents. While mock-trans-
fected oocytes had a whole-cell conductance of 1.1  0.2 S
(n  15) under control conditions, which was marginally in-
creased to 1.3  0.3 S (n  15) after stimulation with IBMX
and forskolin, oocytes expressing CFTR variants increased
whole-cell conductances significantly.
Mutation of residues S422, Y512, and T1471 to either ala-
nine or aspartate variably inhibited or augmented CFTR con-
FIG. 6. CK2 regulation of F508del CFTR. (A) Whole-cell current measured in a F508del-CFTR-expressing oocyte before and after activation
by IBMX/forskolin (1 mM/2 M, respectively) and effects of the CK2 inhibitor TBB (10 M). (B) Summary of the calculated IBMX/forskolin-
activated whole-cell conductances for F508del CFTR and CFTR variants and whole-cell conductances in the presence of TBB. (C) Whole-cell
conductances of CFTR variants relative to F508del CFTR. (D) TBB-inhibited whole-cell conductances of CFTR variants relative to F508del
CFTR. Data indicate means  standard errors of the means. Numbers in parentheses indicate numbers of experiments. Asterisks indicate
significant inhibition by TBB (B) and significant difference from F508del CFTR (unpaired t test and ANOVA) (C and D).
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ductance (Fig. 5B, normalized against wt control for ease of
comparison in Fig. 5C and D). In particular, the TBB sensitiv-
ity of the inhibition of CFTR conductance was significantly
reduced for S422A (Fig. 5B, bars 3 and 4) and Y512D (bars 9
and 10) but was augmented for S422D and almost doubled for
Y512A (Fig. 5B). Rather impressive was the finding that such
increased IBMX/forskolin-induced conductance was com-
pletely inhibited by TBB. These data indicate that apart from
the formerly suggested S511 (39), these other sites within
CFTR appear to be essential for regulation by CK2, especially
the potential SYK site at Y512. We also observed a 50% higher
conductance for S422D and a 50% reduction with the S422A
mutant relative to wt CFTR (compare bar 5 with bars 3 and 1
in Fig. 5B and summary in Fig. 5C). This is consistent with an
important role for S422 phosphorylation in increasing CFTR
activity.
CK2 regulation of F508del CFTR. We further examined the
effects of the alanine and aspartate variants in a F508del CFTR
background.
Figure 6A shows a whole-cell current in F508del-CFTR-
expressing and Xenopus oocytes. The whole-cell current and
conductance are actually very small under control conditions
(only 1.1  0.2 S; n  15), indicating that there is no baseline
Cl conductance in these oocytes. Stimulation with IBMX and
forskolin only slightly, but significantly, activates an additional
whole-cell current which increases the whole-cell conductance
to 3.4  0.6 S (n  15).
As reported earlier (39), we confirmed in F508del CFTR
that this reduced whole-cell Cl conductance is insensitive to
CK2 inhibition (Fig. 6A and B). None of the above mutations
caused significant effects on either of the IBMX/forskolin-
induced whole-cell currents on the F508del background, ex-
cept for Y512A, which increased whole-cell currents signifi-
cantly and was newly demonstrative of inhibition of the
currents by TBB (Fig. 6B and D, bar 4). Notably, elimination
of this SYK site in both wt CFTR and F508del CFTR addi-
tionally enhanced baseline Cl conductance in Xenopus
oocytes in the absence of IBMX and forskolin (Fig. 7). This
suggests that the phosphorylation status of CFTR at Y512
influences CFTR either by keeping the channel closed or by
causing a reduction in CFTR cell surface expression, but in-
dependently of F508, as judged by the enhanced basal CFTR
activity of both Y512A-wt CFTR and Y512A-F508del CFTR
(Fig. 7A and B). Of note, however, the magnitude of the
conductance for the Y512A-F508del CFTR variant was still
small relative to wt CFTR.
Turnover and processing of CFTR bearing Y512 mutations.
As mutation of Y512 in CFTR expressed in oocytes highlights
a possible regulation of CFTR mediated by this residue, we
next analyzed the effect of mutating this residue upon CFTR
turnover and processing. As described above, mutations of
Y512 to A, D, E, and additionally F (an aromatic residue of a
size similar to tyrosine) were introduced into wt-CFTR-pNUT
and the resulting vectors were used to generate stable BHK
cells (Fig. 8A). These results show that steady-state levels of
total CFTR are significantly affected by these variants, with the
least effect being observed with replacement of phenylalanine
by either tyrosine or glutamate (Fig. 8A, lanes 4 and 5). Pro-
cessing of CFTR, however, is strongly affected by the Y512A,
-D, and -E variants but not by the presence of phenylalanine
residue (Fig. 8B).
The turnover and processing of these variants were also
assessed by pulse-chase experiments. Results show that muta-
tion of Y512 to an alanine or an aspartate significantly de-
creases the efficiency of processing of wt CFTR (Fig. 8E)
without a significant impact upon the turnover of the immature
form (Fig. 8D). The presence of the bulky side chain of phe-
nylalanine (more comparable in size to that of tyrosine) or the
longer negatively charged side chain of glutamate again does
not affect the turnover of band B (Fig. 8G), and although
decreasing significantly the efficiency of processing, this decline
is less pronounced than that observed for Y512A or -D (com-
pare Fig. 8H with Fig. 8E).
Levels of CFTR at the membrane are affected by Y512 mu-
tations. In order to further explore the relevance of Y512 for
CFTR trafficking, levels of CFTR at the membrane were as-
sessed for these variants by cell surface biotinylation. Results
show that replacement of Y512 by a negative residue (gluta-
mate) decreases the plasma membrane levels of CFTR and
that the replacement of Y512 by phenylalanine slightly in-
creases the amount of membrane CFTR (Fig. 9).
SYK is an important regulator of CFTR. As studies with
Y512 CFTR variants highlighted the relevance of this residue
in the regulation of CFTR turnover, processing, and function,
we further verified the role of SYK for activation of CFTR. For
FIG. 7. Enhanced baseline CFTR activity by mutation of the SYK
phosphorylation site. (A) Summary of the baseline whole-cell conduc-
tances (before stimulation with IBMX/forskolin) generated in oocytes
expressing wt CFTR and CFTR mutants. (B) Summary of the baseline
whole-cell conductances (before stimulation with IBMX/forskolin)
generated in oocytes expressing F508del CFTR and various CFTR
variants on an F508del background. Data indicate means  standard
errors of the means. Numbers in parentheses indicate numbers of
experiments. Asterisks indicate significant difference from wt CFTR
(ANOVA).
VOL. 31, 2011 CK2 AND SYK REGULATE CFTR 4399
this, we examined the effects of the SYK inhibitor 574711
(Calbiochem, Germany) on activation of wt CFTR and
F508del CFTR in Xenopus oocytes. As shown in Fig. 10, 200
nM SYK inhibitor 574711 largely augmented the whole-cell
currents produced by either wt CFTR or F508del CFTR in
Xenopus oocytes (Fig. 10), to a degree similar to that observed
for Y512A (Fig. 5B). Moreover, inhibition of SYK appears to
sensitize CFTR for inhibition by TBB, judged by the near-
complete post-TBB inhibition of CFTR for this variant (in Fig.
10, compare black bars with white ones, under SYK inhibitor).
To investigate whether this sensitization is specific, we tested
for a possible effect of another kinase site in the vicinity,
namely, serine S519, a putative site for phosphorylation by
Chk1. We thus tested the effect of Chk1 inhibitor 218078
(Calbiochem, Germany). After treatment with a 200 nM con-
centration of this inhibitor, we did not find any significant
effects on wt CFTR conductance, while F508del CFTR con-
ductance was reduced by inhibition of Chk1 (data not shown).
FIG. 8. Biochemical analysis of SYK phosphorylation site variants. (A) Steady-state levels of CFTR bearing Y512 mutations. WB of total
protein (30 g) from BHK cells stably expressing CFTR bearing different mutations. Actin was also assessed as a loading control. (B) Processing
of CFTR at steady state was assessed by densitometry and shown as the ratio of band C to total CFTR (C/B	C), normalized to wt CFTR (black
bars). Amount of mature band C CFTR was also assessed as ratio of band C to actin, again normalized to wt CFTR (grey bars). Asterisks indicate
significant differences from wt CFTR (t test, P 
 0.05). (C and F) BHK cells stably expressing wt, Y512A, Y512D, Y512E, or Y512F CFTR were
analyzed by pulse-chase as in Fig. 2, followed by immunoprecipitation with anti-CFTR 596 Ab. (D, E, G, and H) Electrophoresis, fluorography,
and quantification were also performed as in Fig. 2 but using the ImageQuant software to determine the turnover of the core-glycosylated form
(band B) (D and G) and the efficiency of maturation (E and H). Images and quantitations are representative of a total of 3 to 4 experiments.
Asterisks in panels E and H indicate differences from wt CFTR for the time points indicated (t test, P 
 0.05).
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SYK is expressed in respiratory cell lines and coprecipitates
with CFTR. In order to assess the physiological relevance of
these findings, we used reverse transcription-PCR (RT-PCR)
to assess whether SYK is expressed in human nasal epithelial
cells from CF patients (F508del homozygous) and controls as
well as in three respiratory established cell lines, the submu-
cosal gland cell line Calu-3 and a bronchial cell line homozy-
gous for F508del (with no detectable endogenous expression of
CFTR) virally transduced with either wt (CFBE-wt) or
F508del CFTR (CFBE-F508del). We extracted RNA, applied
RNase-free DNase digestion, and synthesized cDNA with ran-
dom hexamers. This material was used as a template to amplify
a 153-bp fragment with SYK-specific primers. The band ob-
served in all the cDNA samples analyzed, but absent in the
DNase-treated mRNA samples (Fig. 11A), confirmed the spe-
cific amplification of SYK, thus indicating that this kinase is
expressed in all the tissues/cell lines tested (Fig. 11A).
Additionally, we assessed whether SYK precipitates in vivo
with wt CFTR. CFBE cells stably expressing wt CFTR were used to immunoprecipitate CFTR under low-stringency con-
ditions. Immunoprecipitated protein samples were then used
to assess the presence of SYK by WB.
Results show that, after CFTR immunoprecipitation, we were
able to detect SYK and that the kinase is not pulled down in the
bead control (Fig. 11B, upper panel). Data also show that in the
human epithelial respiratory cell lines CFBE-wt and also Calu-3
(data not shown, confirmed n 3), CFTR can interact with SYK.
SYK phosphorylates in vitro CFTR NBD1 at Y512. To fur-
ther strengthen our findings, we then analyzed whether SYK is
able to phosphorylate CFTR NBD1. To this end, purified
recombinant NBD1 (rNBD1) and immunopurified YFP-SYK
were used in an in vitro phosphorylation assay. Results show
that besides catalyzing its autophosphorylation, SYK is also
able to phosphorylate CFTR-NBD1 (Fig. 12).
A similar approach was also performed with Y512-mutated
NBD1, and data show that mutation of this residue completely
abolishes the phosphorylation of rSUMO-NBD1 or decreases
the levels of phosphorylated Myc-NBD1 to those observed for
the control in the absence of SYK, thus confirming that Y512
is the likely site for CFTR phosphorylation by SYK.
FIG. 9. Cell surface expression of CFTR variants. BHK cells stably
expressing either wt, Y512F, or Y512E CFTR were subjected to sur-
face protein biotinylation, followed by streptavidin pulldown. Shown
are WB results for both pulled-down and input fractions, probed with
anti-CFTR 596 monoclonal antibody. As controls for assay specificity,
the intracellular protein -tubulin was also stained, and nonbiotiny-
lated samples (without biotin) were analyzed for each cell line. Blots
shown are representative of three independent experiments.
FIG. 10. Inhibition of SYK activates CFTR. Summary of the
whole-cell conductances generated by wt CFTR (left) and F508del
CFTR (right), measured in the absence or presence of TBB (10 M)
and the SYK inhibitor 574711 (200 nM), relative to the whole-cell
conductances measured under control conditions. Data indicate
means  standard errors of the means. Numbers in parentheses indi-
cate numbers of experiments. Asterisks indicate significant difference
from control (unpaired t test and ANOVA).
FIG. 11. SYK is expressed in human nasal cells and interacts with
CFTR in vivo. (A) Expression of SYK mRNA in human nasal cells and
in respiratory cell lines. (Left panel) Total RNA was extracted from
the submucosal gland cell line Calu-3 (lanes 1 and 2) and from a
bronchial cell line homozygous for F508del (and with no detectable
endogenous expression of CFTR) transduced with either wt (lanes 3
and 4) or F508del (lanes 5 and 6) CFTR. RNA was subjected to
digestion with RNase-free DNase. cDNA was synthesized using
SuperScript II reverse transcriptase, and PCR with primers specific for
SYK was performed in either cDNA (lanes 1, 3, and 5) or mRNA
(lanes 2, 4, and 6) samples. (Right panel) Total RNA was extracted
from human nasal epithelial cells obtained from a non-CF individual
(lane 2) and a CF patient homozygous for F508del (lane 3). cDNA
synthesis and PCR for SYK were performed as described above.
Calu-3 cDNA was included as a positive control. Lane NC, PCR
negative control. Lane M, X174/HaeIII ladder. (B) CFTR forms
complexes in vivo with SYK. CFTR was immunoprecipitated from
CFBE-wt cells. The immunoprecipitated complex was blotted for
SYK. As a positive control, SYK was detected by WB after immuno-
precipitation (1:10 of the immunoprecipitate was loaded). As a nega-
tive control, pulldown was also performed with protein G-agarose
beads and samples were blotted for SYK. Loading controls show
equivalent amounts of SYK and -tubulin in the precleared lysates
(equivalent amounts were assessed).
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DISCUSSION
Regulation of CFTR by CK2. Our primary aim was to further
characterize the role of CK2 in the regulation of CFTR traffic
and function. We present further evidence that CK2-depen-
dent regulation of CFTR has also a major role in electrolyte
transport in native epithelial tissues (Fig. 1) and not only in
cellular models.
Previous data, confirmed here (Fig. 6A), demonstrated that
inhibition of CK2 correlates with reduced CFTR activity (39).
Furthermore, here we show that this effect of pharmacological
CK2 inhibition applies not only to CFTR function as a chloride
channel but also to the processing of wt CFTR. Indeed, our
results show that CK2 activity is also essential for the successful
processing (and membrane trafficking) of CFTR: this may in-
volve direct phosphorylation of CFTR by CK2, previously
shown to occur at S422 (26), or this effect may involve other
targets of CK2 that relate to CFTR-associated proteins.
Interestingly, the Na	/H	 exchanger 3 (NHE3) activity was
also found to be inhibited by the structurally related CK2
inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimid-
azole (DMAT). It was concluded that CK2 binds to the NHE3
C terminus and stimulates basal NHE3 activity by phosphory-
lating a separate single site on the NHE3 C terminus, which
affects NHE3 trafficking (34). Space considerations precluded
a more detailed analysis, but we note that CK2 also controls
important CFTR interactors such as syntaxins that are also
involved in CFTR processing to the plasma membrane (12).
Our analysis included the functional characterization of CK2
sites in CFTR that are involved in its regulation. Serine residue
422, previously identified not only as a consensus site but also
as an actual site for phosphorylation of purified NBD1 by
recombinant CK2, was shown here to be a critical residue, not
for CFTR biogenesis, since neither turnover nor processing
(Fig. 4A to C) is affected by a nonphosphomimic (S422A) or a
phosphomimic (S422D), but for CFTR activity. Furthermore,
although function of S422D CFTR is greatly affected by incu-
bation with TBB, there is no change in its processing in the
presence of this CK2 inhibitor (data not shown).
Functional assessment of these variants in Xenopus oocytes
shows that S422A CFTR has reduced channel function and
that S422D CFTR has increased function compared with wt
CFTR (Fig. 5B and C). These results thus suggest that phos-
phorylation at S422 is involved in the regulation of CFTR
function, contributing to its activation, consistent with its pro-
posed pivotal position in the control of the interaction between
NBD1 and NBD2 (16). In fact, we also observed an increased
sensitivity to TBB for the S422D mutant and a decreased
sensitivity for the S422A nonphosphorylatable mutant, sug-
gesting that the introduction of a negative charge at serine 422
by CK2 as shown in vivo or by PKA (for which serine 422 is also
a consensus site) (7) boosts CFTR sensitivity to CK2 activity,
judged by the enhanced sensitivity to CK2 inhibition. Our data
also suggest a role of residue S422 in modulating the binding of
CK2 to the CFTR surface. The proposed role of this kinase as
a multianchor protein partner responsible for the recruitment
of other proteins to CFTR is evidenced here by the activating
role of S422 (20).
The present study also provides further insight into the role
of residues S511 and T1471. Serine 511 has been previously
implicated in the regulation of CFTR by CK2, as the mutant
S511D was found to be insensitive to TBB in Xenopus oocytes
but to have no major impact on the single-channel behavior of
CFTR (39). Our biochemical data show that this residue is in
fact not critical for CFTR turnover and processing.
More striking, however, are the results for the T1471 vari-
ants. Indeed, data from mammalian cells show that this residue
is critical for CFTR turnover and processing, significantly re-
ducing (T1471A) or completely abolishing (T1471D) the ap-
pearance of mature CFTR. This residue is located very close to
the C terminus of CFTR; thus, its substitution is probably
affecting critical protein-protein interactions (e.g., with
NHERF1) by further augmenting the negative charge in a
region that is essential for CFTR trafficking at the plasma
membrane (14). Strikingly, the patterns of maturation of
F508del CFTR and T1471D are very similar in that neither of
these variants results in a mature form of CFTR (band C).
Moreover, we note the relative insensitivity of both variants to
CK2 inhibition.
The fact that the quality control machinery is more leaky in
Xenopus oocytes (8), where in fact CFTR anterograde traffick-
ing seems to be preferred to the retrograde trafficking and
endocytosis (38, 41), allowed us to characterize functionally
these CFTR variants. The replacement of threonine T1471 by
a noncharged residue reduces CFTR activity, while the addi-
tional negative charge does not affect the activity of CFTR.
Overall results suggest that the T1471 mutation has a detri-
mental effect on the regulation of CFTR by CK2.
FIG. 12. In vitro phosphorylation of CFTR NBD1 by SYK. GFP
control vector or full-length GFP-SYK wt or kinase dead was trans-
fected into HEK293 cells, immunoprecipitated with anti-GFP antibod-
ies using RIPA buffer, and then incubated in vitro with 1 g recombi-
nant Sumo-NBD1 wt or recombinant Sumo-NBD1 Y512F. WB results
are shown to document successful protein precipitation and the pres-
ence of recombinant NBD1 (lower panels).
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Results with T1471, although puzzling, highlight a dual role
of putative CK2 sites in CFTR: potentiation of both CFTR
processing and function but also possible regulation of its C-
terminal specific interactions (which are critical for CFTR sta-
bility at the plasma membrane).
Taken together, our data on CFTR regulation by CK2 sug-
gest opposing effects of residues S422 and T1471, with S422
having an activating role and T1471 having an inhibitory effect.
Regulation of CFTR by spleen tyrosine kinase. Another
interesting finding of the present study was the regulation of
CFTR by SYK, which is a crucial player in many biological
functions, with important roles in hematopoietic cells and in
the regulation of the inflammatory process (23). In our work,
SYK was found to be expressed in cell lines expressing high
levels of CFTR and also in material derived from either CF
patients or healthy controls. Although expression of SYK in
the airway epithelium has been described before (33) and its
interaction with CFTR has been shown in BHK cells (21), we
report here for the first time that it in fact interacts with CFTR
in human epithelial respiratory cells.
As we confirmed that purified CFTR-wt-NBD1 is phosphor-
ylated in vitro by SYK, likely at tyrosine 512, since it does not
occur for CFTR-Y512F-NBD1, characterization of Y512 vari-
ants not only in Xenopus oocytes but also in stably transfected
mammalian cells suggests that phosphorylation of CFTR by
SYK may be involved in the regulation not only of CFTR
membrane levels but also of CFTR activity. Furthermore, our
functional data also show that phosphorylation of Y512 by
SYK may affect the channel regulation by CK2—replacement
of Y512 by a nonphosphomimic residue (Y512A) increases
CFTR sensitivity to TBB, with the opposite being observed for
Y512D.
These data are the first confirmation of this functional in-
teraction between SYK and CK2. Previous observations evi-
denced that CK2 was able only to phosphorylate CFTR pep-
tides corresponding to the sequence PGTIKENIIFGVSY512D
EYRYR, provided that residue Y512 was replaced with
phosphotyrosine (26), strongly suggesting the potential for
hierarchical phosphorylation, i.e., an interaction between CK2
and SYK at S511, the CK2 consensus, depending on a negative
charge at the adjacent tyrosine (26, 27).
Our functional data also show that inhibition of SYK (or
mutation of the potential SYK phosphorylation site) strongly
augments Cl currents in oocytes, even those produced by
F508del CFTR, confirming SYK as a novel target for pharma-
cotherapy of CF, as proposed by our recent study, where this
effect was shown to be partially reversed by WNK4 (21). In-
terestingly, inhibition of SYK with small interfering RNA
(siRNA) also downregulates proinflammatory molecules inter-
leukin 6 (IL-6) and ICAM-1 (40), further reinforcing the rel-
evance of SYK as a target to be knocked down for CF therapy.
Moreover, phosphorylated SYK recruits and activates multiple
downstream signaling molecules, including the small GTPases
Rac1 and Cdc42 (13), the former of which was recently shown
to play a role in CFTR trafficking and membrane anchoring (P.
Matos and P. Jordan, personal communication).
Clarification of the role played by these two kinases in
CFTR membrane trafficking and activity gives further insight
into the complex regulation of the protein, potentially contrib-
uting to the discovery of new potential therapeutic targets for
the treatment of patients with CF, here clearly favored, as
kinase-based mechanisms are among those of higher “drug-
gability.”
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